<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anthrax immunoglobulin (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anthrax immunoglobulin (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anthrax immunoglobulin (United States: Availability limited to Strategic National Stockpile distribution): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="100615" href="/d/html/100615.html" rel="external">see "Anthrax immunoglobulin (United States: Availability limited to Strategic National Stockpile distribution): Drug information"</a> and <a class="drug drug_patient" data-topicid="101043" href="/d/html/101043.html" rel="external">see "Anthrax immunoglobulin (United States: Availability limited to Strategic National Stockpile distribution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F27641451"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Interactions with glucose monitoring systems:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Maltose in immune globulin products, including Anthrasil, may give falsely high blood glucose levels with some point-of-care blood glucose testings systems (for example those based on the GDH-PQQ or glucose-dye-oxidoreductase methods) resulting in inappropriate administration of insulin and life-threatening hypoglycemia. To avoid interference by maltose contained in Anthrasil, perform blood glucose measurement in patients receiving Anthrasil with a glucose-specific method (monitor and test strips).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Thrombosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Thrombosis may occur with immune globulin products, including Anthrasil. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.</p>
<p style="text-indent:-2em;margin-left:2em;">For patients at risk of thrombosis, administer Anthrasil at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871908"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Anthrasil</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F46431545"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote</span>;</li>
<li>
<span class="list-set-name">Blood Product Derivative</span>;</li>
<li>
<span class="list-set-name">Immune Globulin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462689"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2d4637d-255e-4f0a-a6df-4610bfc746f2">Anthrax, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax (inhalational exposure), treatment: Note:</b> Must be administered in combination with appropriate antimicrobial therapy. Not for use as postexposure prophylaxis in combination with vaccination; in animal models, anthrax immune globulin has been shown to reduce vaccine immunogenicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-23979740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-23979740'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose:</i> Dose may be doubled for severe cases in patients &gt;5 kg. Without substantially delaying administration, consider therapeutic thoracentesis and/or abdominal paracentesis prior to or concurrently with administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: IV: 1 vial (~60 units).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i> Consider repeat dosing in patients experiencing substantial hemorrhage, patients with significant compartmental fluid losses, and in patients whose own immune response may be impaired or delayed. The interval between doses should take into account the magnitude of ongoing blood and fluid losses and the clinical status of the patient. Repeat dosing has not been evaluated in humans.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F27765889"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c2d4637d-255e-4f0a-a6df-4610bfc746f2">Anthrax, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax (inhalational exposure), treatment: Note:</b> Must be administered in combination with appropriate antimicrobial therapy. Not for use as postexposure prophylaxis in combination with vaccination; in animal models, anthrax immune globulin has been shown to reduce vaccine immunogenicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-23979740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-23979740'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dose:</i> Select initial dose based on clinical severity. Dose may be doubled for severe cases in patients &gt;5 kg. Single doses &gt;840 units (14 vials) have not been evaluated in humans. Without substantially delaying administration, consider therapeutic thoracentesis and/or abdominal paracentesis prior to or concurrently with administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents &lt;17 years:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;10 kg: IV: 1 vial (~60 units).</p>
<p style="text-indent:-2em;margin-left:8em;">10 to &lt;18 kg: IV: 2 vials (~120 units).</p>
<p style="text-indent:-2em;margin-left:8em;">18 to &lt;25 kg: IV: 3 vials (~180 units).</p>
<p style="text-indent:-2em;margin-left:8em;">25 to &lt;35 kg: IV: 4 vials (~240 units).</p>
<p style="text-indent:-2em;margin-left:8em;">35 to &lt;50 kg: IV: 5 vials (~300 units).</p>
<p style="text-indent:-2em;margin-left:8em;">50 to &lt;60 kg: IV: 6 vials (~360 units).</p>
<p style="text-indent:-2em;margin-left:8em;">≥60 kg: IV: 7 vials (~420 units).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥17 years: IV: 7 vials (~420 units).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i> Consider repeat dosing in patients experiencing substantial hemorrhage, patients with significant compartmental fluid losses, and in patients whose own immune response may be impaired or delayed. The interval between doses should take into account the magnitude of ongoing blood and fluid losses and the clinical status of the patient. Repeat dosing has not been evaluated in humans.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065170"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; administer at the minimum rate of infusion practical; monitor closely.</p></div>
<div class="block dohp drugH1Div" id="F51065171"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F27765890"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="100615" href="/d/html/100615.html" rel="external">see "Anthrax immunoglobulin (United States: Availability limited to Strategic National Stockpile distribution): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4664b86f-e7bc-418d-8558-fe64d243a44e">Anthrax, inhalational exposure; anthrax, soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax, inhalational exposure; anthrax, soft tissue infection (off-label use):</b>
<b>IV: Note:</b> Must be administered in combination with appropriate antimicrobial therapy. <b>NOT </b>for use as postexposure prophylaxis in combination with vaccination as anthrax immune globulin has been shown (in animal models) to reduce vaccine immunogenicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-23979740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-23979740'])">Ref</a></span>). Limited data exist for use in patients with skin and soft tissue infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27983504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27983504'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Initial:</i> 420 units (7 vials); select initial dose based on clinical severity. Dose may be doubled for severe cases. Single doses &gt;840 units (14 vials) have not been evaluated in humans. Without substantially delaying administration, consider therapeutic thoracentesis and/or abdominal paracentesis prior to or concurrently with administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Maintenance: </i>Consider repeat dosing in patients experiencing substantial hemorrhage, patients with significant compartmental fluid losses, and in patients whose own immune response may be impaired or delayed. The interval between doses should take into account the magnitude of ongoing blood and fluid losses and the clinical status of the patient. Repeat dosing has not been evaluated in humans.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991922"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use with caution and infuse at the minimum rate possible; patients with preexisting renal impairment are at a higher risk of developing acute renal dysfunction.</p></div>
<div class="block doha drugH1Div" id="F50989179"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F27864110"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrest, edema, hypotension, peripheral edema</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache (20%; dose dependent)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Glycosuria (dose related), hyperkalemia, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Blood coagulation disorder</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Ascites</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Pain at injection site (9%), swelling at injection site (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Acute respiratory distress, pleural effusion, pulmonary edema</p></div>
<div class="block coi drugH1Div" id="F27641453"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of anaphylaxis or prior severe systemic reaction associated with the parenteral administration of anthrax immune globulin, other human immune globulin preparations, or any component of the formulation; IgA-deficient patients with antibodies against IgA and a history of IgA hypersensitivity</p></div>
<div class="block war drugH1Div" id="F27765878"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aseptic meningitis: Aseptic meningitis syndrome (AMS) has been reported with immune globulin administration; may occur with high doses (&gt;2 g/kg). Syndrome usually appears within several hours to 2 days following treatment; usually resolves within several days after product is discontinued. Conduct a detailed neurological examination and CSF studies in patients exhibiting signs and symptoms of AMS (eg, severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, vomiting) to rule out other causes of meningitis, particularly anthrax meningitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolysis: Intravenous immune globulin products have been associated with antiglobulin hemolysis (acute or delayed); monitor for signs of hemolytic anemia. Cases of hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation (DIC) have been reported. Risk factors associated with hemolysis include high doses (&gt;2 g/kg) given either as a single administration or divided over several days, underlying associated inflammatory conditions, and non-O blood type (FDA, 2012). Monitor for signs and symptoms of hemolysis and consider laboratory monitoring (eg, hemoglobin and hematocrit prior to initiation, 36 to 96 hours postinfusion, and 7 to 10 days postinfusion) in higher risk patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity and anaphylactic reactions can occur; monitor all patients for acute allergic reactions during and following infusion. Administration should occur in a setting where appropriate treatment for hypersensitivity, anaphylaxis, or shock can be administered. Discontinue treatment in patients who develop a severe hypersensitivity reaction. Patients with known antibodies to IgA are at a greater risk of developing severe hypersensitivity; use in these patients is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Patients should be monitored for adverse events, which may be related to the rate of infusion (eg, fever, chills, nausea, vomiting, headache), during and after the infusion; follow closely the recommended infusion rates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Monitor for transfusion-related acute lung injury (TRALI); noncardiogenic pulmonary edema has been reported with immune globulin use. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, and fever in the presence of normal left ventricular function. Usually occurs within 1 to 6 hours after infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Acute renal dysfunction, acute renal failure, osmotic nephropathy, acute tubular necrosis, and proximal tubular nephropathy can rarely occur with immune globulin IV products and has been associated with fatalities; more likely with products stabilized with sucrose (which does not include anthrax immune globulin). Use with caution in any patient with preexisting renal dysfunction and patients at risk of renal dysfunction (eg, elderly, diabetes mellitus, volume depletion, sepsis, paraproteinemia, nephrotoxic medications). In patients at risk of renal dysfunction, ensure adequate hydration prior to administration; the rate of infusion should be minimized. Monitor renal function prior to infusion and periodically thereafter; discontinue if renal function deteriorates.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: <b>[US Boxed Warning]: Thrombosis may occur with immune globulin products even in the absence of risk factors for thrombosis. For patients at risk of thrombosis (eg, advanced age, impaired cardiac output, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors), administer at the minimum infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity such as those with cryoglobulins, fasting chylomicronemia/severe hypertriglyceridemia, or monoclonal gammopathies.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypovolemia: Patients should not be volume depleted prior to initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• IgA deficiency: Increased risk of hypersensitivity, especially in patients with anti-IgA antibodies; use is contraindicated in patients with IgA deficiency with antibodies against IgA and history of IgA hypersensitivity</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; may be at increased risk for renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease, including unknown or emerging viruses and other pathogens. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Maltose: <b>[US Boxed Warning]: Some products may contain maltose, which may result in falsely elevated blood glucose readings with some point-of-care blood glucose testings systems (eg, those based on the GDH-PQQ or glucose-dye-oxidoreductase methods), which may result in inappropriate administration of insulin and subsequent hypoglycemia. Blood glucose should be measured by a glucose-specific method (eg, monitor and test strips). </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p></div>
<div class="block prod-avail drugH1Div" id="F27641450"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Anthrasil: FDA approved March 2015; availability is limited to the US Strategic National Stockpile</p></div>
<div class="block geq drugH1Div" id="F53040771"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52871909"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anthrasil: 60 units (50 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614588"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV infusion only. Use of an in-line filter is optional.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion rate: If adverse reactions occur (eg, flushing, headache, nausea, changes in heart rate or blood pressure), slow the rate of infusion or temporarily stop the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, Infants, Children, and Adolescents &lt;17 years: Initiate infusion at 0.01 mL/kg/minute (maximum initial rate: 0.5 mL/minute) for 30 minutes; may increase the infusion rate by 0.02 mL/kg/minute (maximum rate increase: 1 mL/minute) every 30 minutes as tolerated. Maximum infusion rate: 0.04 mL/kg/minute or 2 mL/minute, whichever is less.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Initiate infusion at 0.5 mL/minute for 30 minutes; may increase the infusion rate by 1 mL/minute every 30 minutes as tolerated. Maximum infusion rate: 2 mL/minute</p></div>
<div class="block adm drugH1Div" id="F27765893"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV infusion only. Use of an in-line filter is optional.</p>
<p style="text-indent:-2em;margin-left:2em;">Infusion rate: If adverse reactions occur (eg, flushing, headache, nausea, changes in heart rate or blood pressure), slow the rate of infusion or temporarily stop the infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Initiate infusion at 0.5 mL/minute for 30 minutes; may increase the infusion rate by 1 mL/minute every 30 minutes as tolerated. Maximum infusion rate: 2 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Preexisting renal impairment or at risk of thrombosis: Administer at the minimum rate of infusion practicable; do not exceed the recommended infusion rate and follow the infusion schedule closely.</p></div>
<div class="block sts drugH1Div" id="F27765881"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store frozen at ≤–15°C (≤5°F) until required for use. Do not refreeze, reuse, or save for future use. Discard any partially used vials. </p></div>
<div class="block usep drugH1Div" id="F53571224"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of inhalational anthrax in combination with appropriate antibacterial drugs (FDA approved in pediatric patients [age not specified] and adults)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Effectiveness is based solely on efficacy studies conducted in animal models of inhalational anthrax. Anthrax immune globulin (human) (AIGIV) does not have direct antibacterial activity, does not cross the blood-brain barrier, and does not prevent or treat meningitis. There have been no studies in the pediatric, geriatric, or obese populations.</p></div>
<div class="block cyt drugH1Div" id="F27661833"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F27661830"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May enhance the thrombogenic effect of Anthrax Immune Globulin (Human).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F27765876"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Human data are not available related to the use of anthrax immune globulin in pregnancy. However, anthrax immune globulin is expected to cross the placenta. Anthrax infection is associated with maternal and fetal death. Criteria for treating pregnant and postpartum women should be the same as nonpregnant women unless other contraindications exist. Dosing of anthrax immune globulin in pregnancy should also follow the same weight-based dosing schedule (Meaney-Delman, 2014).</p></div>
<div class="block mopp drugH1Div" id="F53571227"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function (BUN and serum creatinine) before initial infusion and at appropriate intervals thereafter; urine output periodically; baseline blood viscosity in patients at risk for hyperviscosity; signs and symptoms of hemolysis (hemoglobin and hematocrit prior to initiation, 36 to 96 hours postinfusion, and 7 to 10 days postinfusion in patients at high risk), aseptic meningitis syndrome, hypersensitivity reactions, infusion-related reactions, and transfusion-related acute lung injury</p></div>
<div class="block pha drugH1Div" id="F27765883"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antibodies obtained from pooled human plasma of individuals immunized with the anthrax vaccine provide passive immunity and neutralizes the anthrax toxin by binding to protective antigen (PA) to prevent PA-mediated cellular entry of anthrax edema factor and lethal factor.</p></div>
<div class="block phk drugH1Div" id="F27765884"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 5.7 to 6.8 L </p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 24 to 28 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak : ~2.5 to 4 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58211587"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Anthrasil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Emergent.1">
<a name="Emergent.1"></a>Anthrasil (anthrax immune globulin [human]) [prescribing information]. Winnipeg, Manitoba, Canada: Emergent BioSolutions Canada; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27983504">
<a name="27983504"></a>Cui X, Nolen LD, Sun J, et al. Analysis of anthrax immune globulin intravenous with antimicrobial treatment in injection drug users, Scotland, 2009-2010. <i>Emerg Infect Dis.</i> 2017;23(1):56-65. doi:10.3201/eid2301.160608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/27983504/pubmed" id="27983504" target="_blank">27983504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>FDA Safety Communication: updated information on the risks of thrombosis and hemolysis potentially related to administration of intravenous, subcutaneous and intramuscular human immune globulin products. November 13, 2012. <a href="http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm" target="_blank">http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm327934.htm</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979740">
<a name="23979740"></a>Malkevich NV, Basu S, Rudge TL Jr, et al. Effect of anthrax immune globulin on response to BioThrax (anthrax vaccine adsorbed) in New Zealand white rabbits. <i>Antimicrob Agents Chemother</i>. 2013;57(11):5693-5696. doi:10.1128/AAC.00460-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/23979740/pubmed" id="23979740" target="_blank">23979740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24457117">
<a name="24457117"></a>Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2). doi:10.3201/eid2002.130611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/24457117/pubmed" id="24457117" target="_blank">24457117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anthrax-immunoglobulin-united-states-availability-limited-to-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 109408 Version 51.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
